First Author: R.Zainullin RUSSIA
Co Author(s): M. Bikbov R. Fayzrakhmanov T. Gilmanshin M. Kalanov V. Salavatova
Back to previous
To assess the change in the optical density of the macular pigment in patients with diabetic macular edema, receiving antivasoproliferative therapy.
Ufa Eye Research Institute, Ufa, Russia
We examined 44 patients (47 eyes) with diabetic macular edema caused by diabetes Type 2. The photorecording with the measurement of the optical density of the macular pigment (MPOD) was carried out with reflectometry method using a non-mydriatic fudus camera VISUCAM 500® (Carl Zeiss Meditec AG). All patients underwent an anti-VEGF therapy with ranibizumab in the surgical room under local anesthesia in a dose of 0.5 mg.
The average value of the macular pigment optical density before the treatment was 0.319 ± 0.01 du, after the treatment – 0.492 ± 0.02 du (р=0,012). The MPOD analysis revealed a significant increase in all values in 70.5% of patients after therapy. In 79.4% of patients, as a result of the treatment, the best-corrected visual acuity increased from an average of 0.93 ± 0.04 up to 0.79 ± 0.07 logMAR (р=0,032).
After the antivasoproliferative therapy patients with diabetic macular edema had normalized profiles of the spatial distribution of macular pigment and a significant increase in the quantitative parameters of its optical density, as well as the improvement in visual acuity. Definition of macular pigment optical density provides additional information about the status of macular area and can serve as an indicator of the effectiveness of therapy for diabetic macular edema.